A Text Messaging (SMS) Intervention to Improve Adherence to Stimulant Medication in Adults With ADHD in the Primary Care Setting

NCT04189575 | Unknown

• 1 other identifier: 2018-P-000591
• Study Type: interventional
• Target: 117
• Locations: 1 country
• Sites: 1

Brief Summary

This study will assess the efficacy of the text messaging (SMS-based) disease management intervention to improve adherence to stimulants in adults with Attention Deficit/Hyperactivity Disorder (ADHD) within the Partners primary and psychiatry care settings. Participants in the study will receive customized text messages twice a day, every day, for a duration of 9 months. The text messages will include reminders to adhere to the individualized medication regimen, reminders to call their clinician for a prescription refill followed by reminders to pick up medication from the pharmacy, and educational reminders about ADHD and its treatment

Conditions

Attention Deficit/Hyperactivity Disorder

Keywords

Attention Deficit/Hyperactivity Disorder; ADHD; SMS Intervention

Outcome Measures

Primary Outcomes (1)

• Adherence to Stimulants

  Adherence will be analyzed using the timeliness of stimulant medication prescription renewals over the 9 month period.

  9 months

Study Arms (1)

SMS Intervention

EXPERIMENTAL

All subjects will receive customized text messages twice a day, every day for 9 months that will include reminders to adhere to the individualized medication regimen, reminders to call their clinician for a prescription refill followed by reminders to pick up medication from the pharmacy, and educational reminders about ADHD and its treatment.

Other: SMS Intervention

Interventions

SMS Intervention OTHER

Delivery of text messages will use the Rip Road Mobile platform.

SMS Intervention

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Male and female adults ages 18-55 years
• Receipt of a prescription for stimulant medication by their primary care physician or psychiatrist
• Proficient in English
• Has a cellular phone with text messaging capabilities and is interested in and willing to receive free of charge planned text messages

You may not qualify if:

• Investigator and his/her immediate family
• Unwilling/unable to comply with study procedures

Sponsors & Collaborators

• Massachusetts General Hospital: lead
• Shire Human Genetic Therapies, Inc.: collaborator

Study Sites (1)

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

Location

MeSH Terms

Conditions

Attention Deficit Disorder with Hyperactivity

Condition Hierarchy (Ancestors)

Attention Deficit and Disruptive Behavior Disorders; Neurodevelopmental Disorders; Mental Disorders

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Masking Details: All participants will be assigned to the text message intervention and therefore no masking is necessary.
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Chief of the Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD

Study Record Dates

• First Submitted: December 4, 2019
• First Posted: December 6, 2019
• Study Start: May 24, 2018
• Primary Completion: June 1, 2023
• Study Completion: December 1, 2023
• Last Updated: September 26, 2022

Record last verified: 2022-09

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)